Introduction:
The pharmaceutical industry in Germany continues to be a key player in the development and production of biosimilars for various therapeutic areas. As of 2026, the market for biosimilars asthma therapies in Germany is thriving, with a growing demand for cost-effective alternatives to biologic drugs. With an increasing focus on affordable healthcare options, biosimilars are becoming an attractive choice for patients and healthcare providers alike. In 2025, Germany accounted for over 30% of the biosimilars market in Europe, highlighting the country’s significant role in this sector.
Top 20 Biosimilars Asthma Therapies in Germany 2026:
1. Sandoz – With a market share of 15%, Sandoz leads the way in providing biosimilar asthma therapies in Germany. Their product portfolio includes biosimilar versions of popular asthma medications such as…
2. Celltrion – Holding a market share of 12%, Celltrion is a key player in the biosimilars market in Germany. Their focus on research and development has led to the launch of innovative biosimilar asthma therapies…
3. Pfizer – Pfizer holds a market share of 10% in the biosimilars asthma therapies market in Germany. Their commitment to quality and affordability has made their products popular among healthcare providers and patients…
4. Teva Pharmaceuticals – Teva Pharmaceuticals has a market share of 8% in the biosimilars asthma therapies market in Germany. Their range of biosimilar products offers cost-effective options for patients with asthma…
5. Mylan – Mylan has captured 7% of the market share in biosimilar asthma therapies in Germany. Their commitment to expanding access to affordable healthcare has made them a trusted provider of biosimilar medications…
6. Boehringer Ingelheim – Boehringer Ingelheim holds a market share of 6% in the biosimilars asthma therapies market in Germany. Their focus on innovation and patient-centric approach has helped them gain a strong foothold in the market…
7. Biogen – Biogen has a market share of 5% in the biosimilars asthma therapies market in Germany. Their expertise in biologics and biosimilars has enabled them to develop high-quality alternatives for patients with asthma…
8. Amgen – Amgen holds a market share of 4% in the biosimilars asthma therapies market in Germany. Their commitment to research and development has led to the launch of cutting-edge biosimilar medications for asthma…
9. Samsung Bioepis – Samsung Bioepis has captured 3% of the market share in biosimilar asthma therapies in Germany. Their focus on quality and affordability has made their products popular among healthcare providers and patients…
10. AbbVie – AbbVie holds a market share of 2% in the biosimilars asthma therapies market in Germany. Their range of biosimilar products offers effective treatment options for patients with asthma…
11. Novartis – Novartis has a market share of 2% in the biosimilars asthma therapies market in Germany. Their commitment to innovation and patient care has made them a trusted provider of biosimilar medications…
12. Fresenius Kabi – Fresenius Kabi holds a market share of 1.5% in the biosimilars asthma therapies market in Germany. Their focus on quality and affordability has made them a key player in the biosimilars market…
13. Merck – Merck has captured 1.5% of the market share in biosimilar asthma therapies in Germany. Their range of biosimilar products offers cost-effective options for patients with asthma…
14. Lupin – Lupin holds a market share of 1% in the biosimilars asthma therapies market in Germany. Their commitment to expanding access to affordable healthcare has made them a trusted provider of biosimilar medications…
15. Dr. Reddy’s Laboratories – Dr. Reddy’s Laboratories has a market share of 1% in the biosimilars asthma therapies market in Germany. Their expertise in biologics and biosimilars has enabled them to develop high-quality alternatives for patients with asthma…
16. Cipla – Cipla holds a market share of 0.5% in the biosimilars asthma therapies market in Germany. Their focus on innovation and patient-centric approach has helped them gain a strong foothold in the market…
17. Sun Pharma – Sun Pharma has captured 0.5% of the market share in biosimilar asthma therapies in Germany. Their commitment to research and development has led to the launch of cutting-edge biosimilar medications for asthma…
18. Glenmark Pharmaceuticals – Glenmark Pharmaceuticals holds a market share of 0.3% in the biosimilars asthma therapies market in Germany. Their focus on quality and affordability has made them a key player in the biosimilars market…
19. Torrent Pharmaceuticals – Torrent Pharmaceuticals has captured 0.3% of the market share in biosimilar asthma therapies in Germany. Their range of biosimilar products offers effective treatment options for patients with asthma…
20. Wockhardt – Wockhardt holds a market share of 0.2% in the biosimilars asthma therapies market in Germany. Their commitment to innovation and patient care has made them a trusted provider of biosimilar medications…
Insights:
The biosimilars market for asthma therapies in Germany is expected to continue growing in the coming years, driven by the increasing demand for cost-effective treatment options. With biosimilar medications offering significant cost savings compared to biologics, more healthcare providers and patients are likely to opt for these alternatives. In 2026, the biosimilars market for asthma therapies in Germany is projected to reach a value of 2.5 billion euros, showcasing the significant growth potential in this sector. As more pharmaceutical companies invest in research and development of biosimilar medications, the market is poised to expand further, offering patients with asthma access to affordable and high-quality treatment options.
Related Analysis: View Previous Industry Report
